Macis Debora, Aristarco Valentina, Johansson Harriet, Guerrieri-Gonzaga Aliana, Raimondi Sara, Lazzeroni Matteo, Sestak Ivana, Cuzick Jack, DeCensi Andrea, Bonanni Bernardo, Gandini Sara
Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Cancers (Basel). 2021 Jun 30;13(13):3303. doi: 10.3390/cancers13133303.
Adiponectin and leptin are adipokines secreted by the adipose tissue that are associated with several chronic diseases including cancer. We aimed to compare the immunoassay platform ELLA with an enzyme-linked immunosorbent assay (ELISA) kit and to assess whether the results of the association analyses with breast cancer risk were dependent on the assay used. We measured adiponectin and leptin with ELLA and ELISA on baseline serum samples of 116 Italian postmenopausal women enrolled in two international breast cancer prevention trials. Results were compared with Deming, Passing-Bablok regression and Bland-Altman plots. Disease-free survival was analyzed with the Cox model. There was a good correlation between the methods for adiponectin and leptin (r > 0.96). We found an increased breast cancer risk for very low adiponectin levels (HR for ELLA = 3.75; 95% CI: 1.37;10.25, = 0.01), whereas no significant association was found for leptin levels. The disease-free survival curves were almost identical for values obtained with the two methods, for both biomarkers. The ELLA platform showed a good concordance with ELISA for adiponectin and leptin measurements. Our results support the association of very low adiponectin levels with postmenopausal breast cancer risk, irrespective of the method used. The ELLA platform is a time-saving system with high reproducibility, therefore we recommend its use for biomarker assessment.
脂联素和瘦素是由脂肪组织分泌的脂肪因子，与包括癌症在内的多种慢性疾病相关。我们旨在比较免疫分析平台ELLA与酶联免疫吸附测定（ELISA）试剂盒，并评估乳腺癌风险关联分析的结果是否取决于所使用的检测方法。我们使用ELLA和ELISA对116名参与两项国际乳腺癌预防试验的意大利绝经后女性的基线血清样本进行脂联素和瘦素检测。结果通过戴明回归、帕辛 - 巴布洛克回归和布兰德 - 奥特曼图进行比较。采用Cox模型分析无病生存期。脂联素和瘦素的检测方法之间具有良好的相关性（r>0.96）。我们发现脂联素水平极低时乳腺癌风险增加（ELLA的风险比=3.75；95%置信区间：1.37；10.25，P = 0.01），而瘦素水平未发现显著关联。两种方法获得的值对应的无病生存曲线几乎相同，两种生物标志物均如此。ELLA平台在脂联素和瘦素测量方面与ELISA显示出良好的一致性。我们的结果支持极低脂联素水平与绝经后乳腺癌风险相关，无论使用何种方法。ELLA平台是一个省时且具有高重现性的系统，因此我们推荐将其用于生物标志物评估。
